Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot double-blind dose-escalation study of AGN-214868 in idiopathic overactive bladder
2010-021718-41Phase 2Completed
- Sponsor
- Allergan
- Start
- Sep 2010
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in overactive bladder (OAB) comparing AGN-214868 dose-escalation with Placebo (2 arms). Started Sep 2010; status: completed.
02
Drugs
senrebotase
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2010-021718-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021718-41.